Drugs & Targets Cullinan Oncology, Taiho Pharmaceutical to develop and commercialize CLN-081/TAS6417 for NSCLC May 13, 2022Vol.48 No.19
Drugs & Targets Imfinzi + chemo granted FDA Priority Review for locally advanced or metastatic biliary tract cancer May 06, 2022Vol.48 No.18
Drugs & Targets Aptose granted Fast Track Designation from FDA for HM43239 in relapsed/refractory AML patients and FLT3 Mutation May 06, 2022Vol.48 No.18
Drugs & Targets EC approves Kymriah in relapsed or refractory follicular lymphoma May 06, 2022Vol.48 No.18
Drugs & Targets EC approves Cabometyx as a second-line treatment for radioactive iodine-refractory differentiated thyroid cancer May 06, 2022Vol.48 No.18
Drugs & Targets Myriad Genetics expands partnership with Intermountain Precision Genomics, adding liquid biopsy therapy selection offering May 06, 2022Vol.48 No.18
Drugs & Targets Aadi Bioscience issues unique permanent J-code for Fyarro from CMS May 06, 2022Vol.48 No.18
Drugs & Targets EMA CHMP adopts positive opinion for Tabrecta in METex14 advanced NSCLC April 29, 2022Vol.48 No.17
Drugs & Targets Portage Biotech, NCI, Stimunity enter cooperative R&D agreement to develop STING agonists and anti-RAGE agents for cancer vaccines April 29, 2022Vol.48 No.17
